Agostino Gemelli University Polyclinic

Researchers

• MBMatteo Bruno

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.

  2026-526113-28-00· Phase 4· Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.· Source

• Not yet recruiting

  Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement

  NCT07877298· University Hospital Muenster· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

  NCT07858123· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

  NCT07773727· Phase 2· argenx· Source

• Recruiting

  To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

  NCT07629583· Phase 1· Genentech, Inc.· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Not yet recruiting

  Artificial Intelligence Software (Prostate Intelligence) for Detecting Clinically Significant Prostate Cancer on MRI

  NCT07875491· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

  NCT07444450· Phase 3· Biogen· Source

• Not yet recruiting

  A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy

  2026-527617-29-00· Phase 3· Systimmune Inc.· Source

• Not yet recruiting

  Development of the SC-IBD Self-Care Measurement Scale

  NCT07494227· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· Phase 3· K-Group Beta Inc.· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source

• Recruiting

  Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360

  NCT07323316· Ad scientiam· Source

• Recruiting

  A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

  NCT07412704· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Recruiting

  A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.

  2025-525030-57-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  A Master Regulator of Lipid-Associated Macrophage Function in Cancer

  NCT07848061· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Not yet recruiting

  A Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence

  2026-525961-37-00· Phase 2/3· Centessa Pharmaceuticals UK Limited· Source

• Not yet recruiting

  Prevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma

  2026-526857-33-00· Phase 2· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Not yet recruiting

  ctDNA-guided Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma. The FUTURE Study

  2026-527171-28-00· Phase 4· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Recruiting

  A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)

  2026-525328-10-00· Phase 2· Medica Scientia Innovation Research S.L.· Source

• Not yet recruiting

  DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”

  2026-525268-16-00· Phase 2/3· Universita' Degli Studi Di Torino· Source

• Recruiting

  AI-Based Tools for Stroke Diagnosis, Treatment and Outcome Prediction: a Multicentre Prospective Observational Study

  NCT07924371· Hospital Universitari Vall d'Hebron Research Institute· Source

• Recruiting

  A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

  NCT07705607· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial

  2025-521209-42-00· Phase 4· Fondazione GONO G.I.· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· CSL Behring· Source

• Recruiting

  A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

  NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Not yet recruiting

  Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer in Italy

  NCT07825181· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Not yet recruiting

  Targeting MYC in High-Risk Medulloblastoma

  NCT07694622· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Not yet recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Not yet recruiting

  Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.

  2025-524606-15-00· Phase 3· Tecnimede-Sociedade Tecnico-Medicinal S.A.· Source

• Recruiting

  A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.

  2025-524488-18-00· Phase 2· Astellas Pharma Global Development Inc.· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

Showing 50 of 781.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer47 recruiting
• Colorectal cancer32 recruiting
• Ovarian cancer22 recruiting
• Endometrial cancer21 recruiting
• Pancreatic cancer20 recruiting
• Crohn's disease18 recruiting
• Metastatic breast cancer18 recruiting
• Childhood cancers15 recruiting
• Chronic lymphocytic leukaemia15 recruiting
• Prostate cancer15 recruiting
• Ulcerative colitis15 recruiting
• Bladder cancer14 recruiting
• Cervical cancer14 recruiting
• Fatty liver disease (MASLD/MASH)14 recruiting
• Obesity14 recruiting
• Gastric and oesophageal cancer13 recruiting
• Liver and biliary tract cancer13 recruiting
• Duchenne muscular dystrophy12 recruiting
• Melanoma12 recruiting
• Myasthenia gravis12 recruiting
• Head and neck cancer10 recruiting
• Kidney cancer10 recruiting
• Acute myeloid leukaemia9 recruiting
• Macular degeneration9 recruiting
• Parkinson disease9 recruiting
• Type 2 diabetes9 recruiting
• Lupus (SLE)8 recruiting
• Multiple myeloma8 recruiting
• Rheumatoid arthritis8 recruiting
• Alzheimer disease7 recruiting
• Heart failure6 recruiting
• Liver cirrhosis6 recruiting
• Psoriasis6 recruiting
• Triple-negative breast cancer6 recruiting
• Acute lymphoblastic leukaemia5 recruiting
• Asthma5 recruiting
• Atopic dermatitis (eczema)5 recruiting
• High blood pressure5 recruiting
• Idiopathic pulmonary fibrosis5 recruiting
• Stroke5 recruiting
• Systemic sclerosis (scleroderma)5 recruiting
• Amyloidosis4 recruiting
• Atrial fibrillation4 recruiting
• Coronary artery disease4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Follicular lymphoma4 recruiting
• Glioblastoma4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Sarcoma4 recruiting
• Chronic kidney disease3 recruiting
• COPD3 recruiting
• Epilepsy3 recruiting
• Immune thrombocytopenia (ITP)3 recruiting
• Multiple sclerosis3 recruiting
• Psoriatic arthritis3 recruiting
• Spinal muscular atrophy3 recruiting
• ANCA-associated vasculitis2 recruiting
• Aortic aneurysm2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Depression2 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Graves' disease and hyperthyroidism2 recruiting
• Hidradenitis suppurativa2 recruiting
• HIV2 recruiting
• Hodgkin lymphoma2 recruiting
• Huntington's disease2 recruiting
• IgA nephropathy2 recruiting
• Mantle cell lymphoma2 recruiting
• Meningioma2 recruiting
• Myocarditis2 recruiting
• Sjögren's disease2 recruiting
• Thyroid cancer2 recruiting
• Ankylosing spondylitis1 recruiting
• Aortic stenosis1 recruiting
• Cerebral palsy1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coeliac disease1 recruiting
• Congenital heart disease1 recruiting
• Cytomegalovirus infection1 recruiting
• Diabetic eye disease1 recruiting
• Down syndrome1 recruiting
• Dystonia1 recruiting
• Endometriosis1 recruiting
• Essential tremor1 recruiting
• Hypothyroidism1 recruiting
• Irritable bowel syndrome1 recruiting
• Mesothelioma1 recruiting
• Migraine1 recruiting
• Myelodysplastic syndromes1 recruiting
• Narcolepsy1 recruiting
• Neuroendocrine tumours1 recruiting
• Osteoporosis1 recruiting
• Peripheral artery disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Type 1 diabetes1 recruiting
• Vitiligo1 recruiting

Closed trials

• Withdrawn

  Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

  NCT07039422· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.

  2025-523984-39-00· Phase 2· Gilead Sciences Inc.· Source

• Completed

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Completed

  SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy

  2025-521748-39-00· Phase 4· Universita Cattolica Del Sacro Cuore· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

• Active, not recruiting

  A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

  NCT07260669· Phase 2· Gesynta Pharma AB· Source

• Completed

  Diagnostic Accuracy of Eus Fnb in Difficult to Reach Lesions

  NCT07621536· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Completed

  Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300

  NCT07592104· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Recruiting

  A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

  NCT07139873· Phase 3· Dizal Pharmaceuticals· Source

• Completed

  A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

  NCT04892017· Phase 1/2· Deciphera Pharmaceuticals Inc.· Source

• Completed

  A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.

  2023-507705-34-00· Phase 3· Alvotech Swiss AG· Source

• Terminated

  An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

  NCT06961344· Phase 2· Tisento Therapeutics· Source

• Completed

  A trial to learn how safe saruparib is and how well it works in people with advanced ovarian cancer

  2024-519044-32-00· Phase 1/2· AstraZeneca AB· Source

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Recruiting

  AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  NCT06991114· Phase 2· Artiva Biotherapeutics, Inc.· Source

• Completed

  A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

  NCT06685718· Phase 1· BeOne Medicines AG· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma

  2024-515162-13-00· Phase 3· AstraZeneca AB· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.

  NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

  2024-515539-31-00· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Prevalence of Disorders of Gut-Brain-Interaction in Pediatric Patients With In-remission Inflammatory Bowel Disease

  NCT07539077· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Active, not recruiting

  Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

  NCT06806293· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

  NCT06255028· Phase 1· Century Therapeutics, Inc.· Source

• Recruiting

  A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

  NCT06555419· Phase 1· Biogen· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Completed

  Efficacy and Safety of REL-1017 for Major Depressive Disorder

  2023-507399-27-00· Phase 3· Mggm LLC· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  NCT06717698· Phase 2· Novo Nordisk A/S· Source

• Completed

  Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

  NCT06544733· Phase 2/3· Gilead Sciences Inc.· Source

• Completed

  A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  NCT06312020· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis

  2024-515470-26-00· Phase 2· Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S· Source

• Completed

  Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.

  NCT06447506· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511360-87-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

  NCT06317285· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT06603077· Phase 2· Avalo Therapeutics, Inc.· Source

• Completed

  Residents' Learning Curve of Intraoperative Transit-time Flowmetry and High-frequency Ultrasound in CABG (LEARNERS)

  NCT06589323· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Completed

  A Phase 2b Study of Zagociguat in Patients With MELAS

  NCT06402123· Phase 2· Tisento Therapeutics· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· AstraZeneca· Source

• Completed

  Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study

  2023-509088-26-00· Phase 2· Fondazione GONO G.I.· Source

• Completed

  A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome

  2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Active, not recruiting

  A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

  NCT06315322· Phase 3· UCB Biopharma SRL· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

  NCT06444451· Phase 2· Sanofi· Source

Showing 50 of 290.

Conditions

Diseases this institution publishes on or runs trials for.

• Ovarian cancer157 works · 57 trials
• Stroke139 works · 14 trials
• Heart failure125 works · 9 trials
• Obesity114 works · 22 trials
• Lung cancer102 works · 90 trials
• Endometrial cancer99 works · 36 trials
• Atrial fibrillation95 works · 6 trials
• Liver and biliary tract cancer84 works · 39 trials
• Coronary artery disease72 works · 12 trials
• Colorectal cancer67 works · 57 trials
• Ulcerative colitis62 works · 36 trials
• Crohn's disease59 works · 32 trials
• Cervical cancer57 works · 24 trials
• Prostate cancer54 works · 24 trials
• Melanoma51 works · 22 trials
• Kidney cancer45 works · 18 trials
• Migraine45 works · 3 trials
• Pancreatic cancer44 works · 29 trials
• Sarcoma36 works · 10 trials
• Triple-negative breast cancer34 works · 16 trials
• Atopic dermatitis (eczema)30 works · 20 trials
• Fatty liver disease (MASLD/MASH)30 works · 20 trials
• Systemic sclerosis (scleroderma)28 works · 17 trials
• Duchenne muscular dystrophy25 works · 25 trials
• Glioblastoma25 works · 8 trials
• Psoriasis24 works · 13 trials
• Spinal muscular atrophy22 works · 14 trials
• Amyloidosis21 works · 6 trials
• Bipolar disorder21 works · 0 trials
• Myocarditis20 works · 2 trials